title: [EFFICIENCY OF COCARNIT IN COMPLEX THERAPY OF PATIENTS WITH SYSTEM DISEASES OF CONNECTING FABRIC WITH DEFEAT OF MYOCARDIUM AND DISPLAYS OF CARDIAC INSUFFICIENCY].
abstract: In clinical trial included 41 patient with clinic-instrumental dates, which said about myocardium dysfunction and system diseases of connecting fabric and displays of CCI I-III of functional class (FC). Including of complex metabolic drug Cocarnit in standard therapy of systemdiseases of connecting fabric was instrumental in more expressed clinical improvement of patientsclinical dates in 15 days of supervision: a weakness diminished on 66.67%, shortbreathing at the insignificant physical loading--on 23.81%, at the ordinary physical loading--on 47.62%, at the megascopic physical loading--on 19.05%, pain in area of heart--on 42.85%, there are interruptions in-process heart--on 28.57%, oedematousness of shins--on 57.14%, sense of numbness, burning, sensitiveness to cold of extremities--on 57.14%. Quantity of patients with III FC diminished on 5 (23.81%), in a control group--on 2 (10%). It implementation of test with the 6-minute walking more expressed increase of the overcame distance is set for the patients of basicgroup--on 15.46% as compared to a control group--on 7.01%. Cocarnit patients estimatedpositively; side effects with subsequent abolition of drug, were not. Laboratory indexes (AlAT, AsAT, bilirubin, kreatinine, haemoglobin) at the end of trial did not change considerably, that confirmed good bearableness of drug.
authors.forename: A
authors.initials: A
authors.lastname: Kuryata
authors.forename: T
authors.initials: T
authors.lastname: Lysunec
authors.forename: O
authors.initials: O
authors.lastname: Noda
mesh_terms: D000255:Adenosine Triphosphate / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000787:Angina Pectoris / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D009202:Cardiomyopathies / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D003238:Connective Tissue / Q000187:drug effects* / Q000473:pathology; D003404:Creatinine / Q000097:blood; D004338:Drug Combinations; D004417:Dyspnea / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D005260:Female; D005998:Glycine / Q000627:therapeutic use; D006333:Heart Failure / Q000097:blood / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D006987:Hypesthesia / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D009536:Niacinamide / Q000627:therapeutic use; D013835:Thiamine Pyrophosphate / Q000627:therapeutic use; D014805:Vitamin B 12 / Q000627:therapeutic use
chemical_list: D002316:Cardiotonic Agents; D004338:Drug Combinations; D006454:Hemoglobins; D009536:Niacinamide; D000255:Adenosine Triphosphate; D003404:Creatinine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D014805:Vitamin B 12; D013835:Thiamine Pyrophosphate; D001663:Bilirubin; D005998:Glycine